Myeloperoxidase (MPO)
Request package insert information
Product Features
The linearity of the assay is from 50-1300 ng/mL (9.5-247.0 mU/mL) in human heparin plasma with intra-assay %CV of 1.0-3.5 % and an inter-assay %CV of 1.5-4.5%. The following substances normally present in the plasma are tested at levels equal to the following concentrations: ascorbic acid produced less than 15% deviation when tested up to 0.5 mM; bilirubin (free), conjugated bilirubin, and triglycerides produced less than 10% deviation when tested up to 40 mg/dL, 2.5 mg/dL, and 1000 mg/dL, respectively.
Assay Principle
In Diazyme’s MPO enzymatic assay, myeloperoxidase activity is obtained through a two-step reaction by subtracting non- MPO peroxidation from total peroxidation. In the first step, total peroxidation rate A is measured through the reaction of total peroxidases in the sample with hydrogen peroxide, 4-AA and phenol in the reagent; in the second step, an MPO specific inhibitor is added to the reaction mixture to obtain the non-MPO activity. As the result of the two-step reaction, the specific MPO activity is obtained from subtracting the non-MPO activity from the total peroxidase activity, or equals to the reaction rate A (first step) minus the reaction rate B (second step).
Intended use
The Diazyme MPO Enzymatic Assay Kit is for the in vitro quantitative determination of Myeloperoxidase in human plasma to be used in conjunction with clinical history for evaluation of cardiac inflammatory conditions and risk of cardiac events. For in vitro diagnostic use.
Product Catalog Number Packaging Method/Format
Kit (300 Tests)
 DZ178A-K
 R1: 2 x 24 mL
R2: 2 x 12 mL
R3: 2 x 9 mL

Enzymatic/Rate
Liquid Stable
Calibrator DZ178A-Cal 4 x 0.5 mL (2 levels)  
Control DZ178A-Con 6 x 0.5 mL (2 levels)